Researchers Submit Patent Application, "2019-Ncov (Sars-Cov-2) Vaccine", for Approval (USPTO 20240108715).
In: Vaccine Weekly, 2024-04-26, S. 3953-3953
serialPeriodical
Zugriff:
A patent application has been submitted for a potential vaccine for the 2019-nCoV (SARS-CoV-2) virus. The inventors have developed polynucleotides that encode the spike protein of the virus, which can be used to produce antigens for large-scale production of the vaccine. The spike protein produced by these polynucleotides can elicit an immunoprotective response and the production of neutralizing antibodies. The invention also includes the use of viral vectors, RNA vaccines, DNA plasmids, fusion proteins, and virus-like particles for the prevention and treatment of 2019-nCoV infection. [Extracted from the article]
Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "2019-Ncov (Sars-Cov-2) Vaccine", for Approval (USPTO 20240108715).
|
---|---|
Zeitschrift: | Vaccine Weekly, 2024-04-26, S. 3953-3953 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1074-2921 (print) |
Schlagwort: |
|
Sonstiges: |
|